Dalas Biotech Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.48 Cr
as on 24-10-2024
- Company Age 35 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.75 Cr
as on 24-10-2024
- Satisfied Charges ₹ 137.12 Cr
as on 24-10-2024
- Revenue 68.68%
(FY 2023)
- Profit 36.47%
(FY 2023)
- Ebitda 55.37%
(FY 2023)
- Net Worth 0.45%
(FY 2023)
- Total Assets 63.26%
(FY 2023)
About Dalas Biotech
The Corporate was formerly known as Sudman Laboratories Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 4.48 Cr.
The company currently has active open charges totaling ₹7.75 Cr. The company has closed loans amounting to ₹137.12 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sangita Rajani, Deepika Rajani, Mukesh Kumar, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232RJ1989PLC005056
- Company No.
005056
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
18 Jul 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Alwar, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Dalas Biotech Limited offer?
Dalas Biotech Limited offers a wide range of products and services, including Turnkey Consultants & Solutions, Project Handling Services, Water Treatment Chemicals, Antibacterial Drugs, Penicillin G Injections, Antibiotic Tablets & Capsules, Cephalexin Tablets.
Who are the key members and board of directors at Dalas Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sangita Rajani  | Whole-Time Director | 25-Mar-2015 | Current |
| Deepika Rajani | Director | 24-Sep-2016 | Current |
Mukesh Kumar  | Director | 15-Mar-2021 | Current |
| Shambhu Yadav | Director | 06-Jan-2023 | Current |
Financial Performance of Dalas Biotech.
Dalas Biotech Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 68.68% increase. The company also saw a substantial improvement in profitability, with a 36.47% increase in profit. The company's net worth moved up by a moderate rise of 0.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dalas Biotech?
In 2023, Dalas Biotech had a promoter holding of 99.99% and a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 10 Nov 2023 | ₹1.25 Cr | Open |
Hdfc Bank Limited Creation Date: 27 Jun 2023 | ₹1.50 Cr | Open |
Others Creation Date: 26 Oct 2021 | ₹5.00 Cr | Open |
How Many Employees Work at Dalas Biotech?
Dalas Biotech has a workforce of 226 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dalas Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dalas Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
